RNA binding motif protein Y-linked family 1 member EGenealiases: []
Q-omics provides the consensus-scored RBMY1E profile across patient tissues and cancer cell-line models. RBMY1E expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RBMY1E is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, RBMY1E RNA expression shows 1,368 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight BRCA, KIRC, and DLBC as cancer lineages where RBMY1E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBMY1E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBMY1E survival associations across molecular data types. RBMY1E RNA expression shows survival associations in the most cancer types (8), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBMY1E RNA expression–survival associations across cancer types. High RBMY1E expression shows unfavorable associations in BRCA, LUAD, LUSC, PCPG, THCA and GBM. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for RBMY1E RNA expression.
This table summarizes RBMY1E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RBMY1E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBMY1E shows lower tumor expression in KIRC and higher tumor expression in LIHC. The KIRC box plot shows higher RBMY1E RNA expression in normal versus tumor tissue (log2 FC = −0.010, t-test p = .002).
This table shows molecular features associated with RBMY1E in patient tissues and cancer cell lines. In patient samples, RBMY1E shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, RBMY1E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
